[출처/시간] MT Newswires - 12:51 PM ET, 05/27/2026
12:51 PM EDT, 05/27/2026 (MT Newswires) -- Insulet's (PODD) voluntary global medical device correction affecting Omnipod 5, DASH and Eros Pods due to manufacturing issues that could result in insulin under-delivery is disappointing but does not alter the company's long-term outlook, RBC Capital Markets said in a note.
RBC analysts said about 8.5% of 2025 global Omnipod Pod production is impacted, with 24 serious adverse events reported but no deaths. The company expects up to $50 million in non-GAAP costs, primarily in the second quarter.
Insulet said the issue will not affect its 2026 guidance or 2026-2028 targets and added it has sufficient supply to replace impacted Pods without disrupting shipments, product availability or new customer starts.
리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.